{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.9","upperLimit":"25.4","value":"22.9"},{"groupId":"OG001","lowerLimit":"15.6","upperLimit":"27.6","value":"20.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization until death. The length of this interval was estimated as the date of death minus the date of randomization plus 1 day. Participants who were still alive at the time of analysis were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pazopanib 800 mg (tablets) administered orally once a day","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Matching Placebo administered orally once a day","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Randomization until death (up to 2 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}